Page last updated: 2024-10-28

fasudil and Parkinson Disease, Secondary

fasudil has been researched along with Parkinson Disease, Secondary in 2 studies

fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.

Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Li, YH1
Yu, JW1
Xi, JY1
Yu, WB1
Liu, JC1
Wang, Q1
Song, LJ1
Feng, L1
Yan, YP1
Zhang, GX1
Xiao, BG1
Ma, CG1
Tönges, L1
Frank, T1
Tatenhorst, L1
Saal, KA1
Koch, JC1
Szego, ÉM1
Bähr, M1
Weishaupt, JH1
Lingor, P1

Other Studies

2 other studies available for fasudil and Parkinson Disease, Secondary

ArticleYear
Fasudil Enhances Therapeutic Efficacy of Neural Stem Cells in the Mouse Model of MPTP-Induced Parkinson's Disease.
    Molecular neurobiology, 2017, Volume: 54, Issue:7

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals

2017
Inhibition of rho kinase enhances survival of dopaminergic neurons and attenuates axonal loss in a mouse model of Parkinson's disease.
    Brain : a journal of neurology, 2012, Volume: 135, Issue:Pt 11

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; 1-Methyl-4-phenylpyridinium; Animals; Axons; Behavior

2012